Effect of Treatment Dairy for Spasticity

Effect of Treatment Dairy on Botulinum Toxin Treatment for Muscle Overactivity (Spasticity). A Randomised Cross-over Study.

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03384927

Enrollment

Registered

2017-12-28

Start date

2017-12-11

Completion date

2025-12-30

Last updated

2025-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spasticity, Muscle

Keywords

Treatment diary

Brief summary

1. Assessing whether the treatment diary can help optimize the overall treatment of patients. 2. To assess whether the patient finds the treatment diary useful and worth spending time on. Also if the patient finds it easier to evaluate the treatment and, if necessary, set new goals. 3. To assess whether the patient's quality of life is increased by the use of the treatment diary.

Detailed description

Hypothesis: A treatment diary will increase the patient's awareness of which spasticity symptoms are significant and can enable the patients to evaluate the treatment more easily. This will result in more relevant treatment goals. At the same time the treatment can be better addressed to the individual patient at routine controls. In addition, the treatment diary will result in closer cooperation between the physiotherapists and occupational therapists and the physician who administers the botulinum toxin. This collaboration is expected to lead to better common goals and optimization of treatment. Finally, it is expected that the above will help to increase the patient's quality of life.

Interventions

None listed

Study design

Observational model

CASE_CROSSOVER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients must have received at least two previous treatments before inclusion, ie. with approx. 3 months apart, and it is assessed that the patients have good effect of the treatments in relation to the agreed treatment goals.

Exclusion criteria

* Patients where changes are planned regarding their treatment for muscle overactivity during the study period. Patients where the disease is not stable and where it may have a major influence on the treatment effect of botulinum toxin treatment during the study period and where it can be difficult to set SMART (Specific, Measurable, Accepted, Realistic, Timed) goals. Patients who have previously been treated and have used a treatment diary in connection with the botulinum toxin treatment. Patients who can not collaborate on completing goals and evaluating treatment effect due to language or cognitive problems. Patients who at the same time are being treated with botulinum toxin in the bladder. If significant changes occur in the patient's health, which may involve new cancer, stroke, multiple sclerosis attack, etc. during the study period, the participant will be withdrawn from the study.

Design outcomes

Primary

Measure	Time frame	Description
Patient becomes more satisfied with their treatment using the treatment diary	October 2019	To assess if the patient becomes more satisfied with their treatment using the treatment diary. This is assessed by a change in the score on the treatment assessment questionnaire (Questionnaire 1).

Secondary

Measure	Time frame	Description
To assess if the patient's quality of life is improved using the treatment diary.	October 2019	To assess if the patient's quality of life is improved using the treatment diary. This is assessed by a change in the score on the quality of life, SF-12 (Questionnaire 2)
The patients' assessment of the treatment diary will be described (Questionnaire 3).	October 2019	the patients' assessment of the treatment diary will be described (Questionnaire 3).

Countries

Denmark

Outcome results